176 related articles for article (PubMed ID: 37909017)
1. Targeting STEAP1 as an anticancer strategy.
Nakamura H; Arihara Y; Takada K
Front Oncol; 2023; 13():1285661. PubMed ID: 37909017
[TBL] [Abstract][Full Text] [Related]
2. Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer.
Jin Y; Lorvik KB; Jin Y; Beck C; Sike A; Persiconi I; Kvaløy E; Saatcioglu F; Dunn C; Kyte JA
Mol Ther Oncolytics; 2022 Sep; 26():189-206. PubMed ID: 35860008
[TBL] [Abstract][Full Text] [Related]
3. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK
Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154
[TBL] [Abstract][Full Text] [Related]
4. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer.
Xu M; Evans L; Bizzaro CL; Quaglia F; Verrillo CE; Li L; Stieglmaier J; Schiewer MJ; Languino LR; Kelly WK
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011027
[TBL] [Abstract][Full Text] [Related]
5. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
6. Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells.
Iijima K; Nakamura H; Takada K; Hayasaka N; Kubo T; Umeyama Y; Iyama S; Miyanishi K; Kobune M; Kato J
Oncol Lett; 2021 Jul; 22(1):546. PubMed ID: 34335918
[TBL] [Abstract][Full Text] [Related]
7. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using
Carrasquillo JA; Fine BM; Pandit-Taskar N; Larson SM; Fleming SE; Fox JJ; Cheal SM; O'Donoghue JA; Ruan S; Ragupathi G; Lyashchenko SK; Humm JL; Scher HI; Gönen M; Williams SP; Danila DC; Morris MJ
J Nucl Med; 2019 Nov; 60(11):1517-1523. PubMed ID: 31053681
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
9. Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1).
Oosterheert W; Gros P
J Biol Chem; 2020 Jul; 295(28):9502-9512. PubMed ID: 32409586
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
Danila DC; Szmulewitz RZ; Vaishampayan U; Higano CS; Baron AD; Gilbert HN; Brunstein F; Milojic-Blair M; Wang B; Kabbarah O; Mamounas M; Fine BM; Maslyar DJ; Ungewickell A; Scher HI
J Clin Oncol; 2019 Dec; 37(36):3518-3527. PubMed ID: 31689155
[TBL] [Abstract][Full Text] [Related]
11. Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges.
Barroca-Ferreira J; Pais JP; Santos MM; Goncalves AM; Gomes IM; Sousa I; Rocha SM; Passarinha LA; Maia CJ
Curr Cancer Drug Targets; 2018; 18(3):222-230. PubMed ID: 28460619
[TBL] [Abstract][Full Text] [Related]
12. STEAP1 is overexpressed in cancers: a promising therapeutic target.
Moreaux J; Kassambara A; Hose D; Klein B
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):148-55. PubMed ID: 23142226
[TBL] [Abstract][Full Text] [Related]
13. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Doran MG; Watson PA; Cheal SM; Spratt DE; Wongvipat J; Steckler JM; Carrasquillo JA; Evans MJ; Lewis JS
J Nucl Med; 2014 Dec; 55(12):2045-9. PubMed ID: 25453051
[TBL] [Abstract][Full Text] [Related]
14. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
15. Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition.
Jiao Z; Huang L; Sun J; Xie J; Wang T; Yin X; Zhang H; Chen J
Histochem Cell Biol; 2020 Aug; 154(2):215-230. PubMed ID: 32382787
[TBL] [Abstract][Full Text] [Related]
16. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM
Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452
[TBL] [Abstract][Full Text] [Related]
17. Six-transmembrane epithelial antigen of the prostate 1 is associated with tumor invasion and migration in endometrial carcinomas.
Sun J; Ji G; Xie J; Jiao Z; Zhang H; Chen J
J Cell Biochem; 2019 Jul; 120(7):11172-11189. PubMed ID: 30714206
[TBL] [Abstract][Full Text] [Related]
18. Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer.
Guo L; Xie H; Zhang Z; Wang Z; Peng S; Niu Y; Shang Z
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358202
[TBL] [Abstract][Full Text] [Related]
19. Six-transmembrane epithelial antigen of the prostate 1 protects against increased oxidative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer.
Nakamura H; Takada K; Arihara Y; Hayasaka N; Murase K; Iyama S; Kobune M; Miyanishi K; Kato J
Cancer Gene Ther; 2019 Sep; 26(9-10):313-322. PubMed ID: 30401882
[TBL] [Abstract][Full Text] [Related]
20. STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.
Rocha SM; Nascimento D; Cardoso AM; Passarinha L; Socorro S; Maia CJ
Mol Med Rep; 2023 Feb; 27(2):. PubMed ID: 36660947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
